• 1\. ≥40 years old, male;

• 2\. Postoperative pathology showed prostate adenocarcinoma;

• 3\. Postoperative pathological stage pN0 or pNx;

• 4\. PSA decline \< 0.1ng/ml within 8 weeks after radical prostate cancer surgery for at least 6 months

• 5\. Biochemical recurrence (PSA rose twice in a row, with an interval of ≥2 weeks and absolute value \> 0.2ng/ml), and traditional imaging (bone scan and CT/MRI scan) did not show local recurrence and distant metastasis.

• 6\. Have one or more of the following risk factors:

‣ Postoperative CAPRA-S score ≥6 points;

⁃ The pathological score of radical surgery for prostate cancer was Gleason 8-10;

⁃ The highest postoperative biochemical recurrence PSA \> 0.5ng/ml;

⁃ Postoperative pathological stage PT3/T4;

⁃ PSADT \< 10 months;

• 7\. ECOG status is 0-1;

• 8\. Life expectancy greater than 10 years;

• 9\. Adequate hematological and organ function tests within 4 weeks prior to the first study treatment, as defined below:

‣ Neutrophil count (ANC)≥1.5×10\^9/L (no granulocyte colony-stimulating factor for 2 weeks prior to cycle 1, day 1);

⁃ Platelet count (PLT)≥100×10\^9/L (no transfusion within 2 weeks prior to day 1 of cycle 1);

⁃ Hemoglobin (Hb) ≥90g/L

⁃ Serum creatinine (Cr)≤1.5×ULN or creatinine clearance \> 50ml/min;

⁃ Total bilirubin (BIL)≤1.5×ULN;

⁃ Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) level ≤2.5×ULN;

⁃ International Standardized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5×ULN;

⁃ Left ventricular ejection fraction (LVEF) ≥50%;

• 10\. The subject is willing and understands to sign the informed consent and is able to comply with the agreement.